Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (October 2024)
34 slides from Maat Pharma's investor presentation, October 2024
Slide 1: Enhancing Survival through Microbiome Innovation
Enhancing Survival through Microbiome Innovation October 2024
Slide 2: Disclaimer
MaaT Pharma October 2024 2 Disclaimer This document has been prepared by MaaT Pharma (the "Company") The information contained in this document has not been subject to This document contains certain forward-looking statements. These and is for information and background purposes only. independent ve
Slide 3: Late-Stage Biotech leading Microbiome Immunomodulator Innovation in Oncology
MaaT Pharma 3 Late-Stage Biotech leading Microbiome Immunomodulator Innovation in Oncology MaaT013 in Phase 3 in aGvHD Deep oncology pipeline Finance Recruitment completed for Phase 3 Donor-derived and co-culture Revenues of MaaT013 in aGvHD in aGvHD in Europe, expecting platforms driving candidate
Slide 4: Host–Microbiota Interactions are Critical for a Functional Immune System
MaaT Pharma October 2024 4 Host – Microbiota Interactions are Critical for a Functional Immune System A rich & diversified gut ecosystem actively 01 modulates the immune system functionality. Diversity in microbial species leads to the production of a wide range of metabolites, 02 such as short-chai
Slide 5: In Oncology, a Higher Gut Microbiome Diversity is Associated with Increased Survival
MaaT Pharma October 2024 5 In Oncology, a Higher Gut Microbiome Diversity is Associated with Increased Survival Hematopoietic Stem Celle Transplation (HSCT) Immune Checkpoint Inhibitor (ICI) Higher survival rate in patients Lower incidence and lower mortality Higher response rate to ICI* in patients
Slide 6: An Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates
MaaT Pharma October 2024 6 An Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates Driving near-term value Progressing next-generation Leading capabilities with the donor-derived MET-N platform co-cultured scalable MET-C platform in microbiome drug production MaaT013 MaaT034 MaaT033
Slide 7: AI-driven Research Engine Powered by Metagenomics Enabling Candidate Selection
MaaT Pharma October 2024 7 AI-driven Research Engine Powered by Metagenomics Enabling Candidate Selection DATA Healthy Selected Native Therapeutics donors MET-N Leading Platform AI ENGINE Leading discovery and AI-driven platform DATA for Microbiome for selecting the best candidates and Patients Disc
Slide 8: A Strong Pipeline With Multiple Near-Term Value Inflection Milestones
MaaT Pharma October 2024 8 A Strong Pipeline With Multiple Near-Term Value Inflection Milestones Platform Program Indication Preclinical Phase I Phase II Phase III Upcoming milestone ARES GI-ORR January 2025 MaaT013 EAP ongoing: 180 pts treated EBMT Data April 2024 PICASSO (IST) Results Q4.24/ Q1.25
Slide 9: Targeting Multiple Attractive Markets with Unmet Medical Need
MaaT Pharma 9 Targeting Multiple Attractive Markets with Unmet Medical Need MaaT03X MaaT034 Multiple fields MaaT033 ~1 to 5b€ 1 ~500m€ 1 MaaT013 ~250m€ Improvement Long-term 3rd line of survival for Solid Tumors in Expansion aGvHD allo-HSCT combination with ICI (Immune / inflammatory) 1L :10k patien
Slide 10: Driving Near-Term Value with the Donor-Derived MET-N Platform
Driving Near-Term Value with the Donor- Derived MET-N Platform MET-N
Slide 11: Immuno-Modulation with MaaT013: A Maximum-Density Product for Fast Engraftment
MaaT Pharma MaaT013 October 2024 11 Immuno-Modulation with MaaT013: A Maximum-Density Product for Fast Engraftment in Acute Situations Pooled microbiota: high-richness, high-diversity, full ecosystem 01 Characteristics Microbiome Therapy containing Butycore® Non immunosuppressive treatment Current A
Slide 12: Understanding and Addressing Acute Graft versus Host Disease
MaaT Pharma MaaT013 aGvHD October 2024 12 Understanding and Addressing Acute Graft versus Host Disease → Acute Graft-versus-Host Disease, a severe complication following allo-HSCT → 50% of Allo-HSCT Patients at Risk In a GvHD, d o no r im m une c e lls a t t a c k t he re c ip ie nt 's t is s ue s p
Slide 13: Unmet Medical Need: aGvHD Resistant to Steroids and Ruxolitinib
MaaT Pharma MaaT013 aGvHD September 2024 13 Unmet Medical Need: Acute Graft-versus-Host Disease (aGvHD) Resistant to Steroids and Ruxolitinib (3rd line of treatment) Treatment Paradigm Lack of effective therapy Corticosteroids are the 1st line of treatment, but approximately There is no approved dru
Slide 14: MaaT013 Restores Immune Homeostasis and Gut Barrier Integrity
MaaT Pharma MaaT013 aGvHD October 2024 14 MaaT013 Restores Immune Homeostasis and Gut Barrier Integrity Re s t orat ion of b a rrie r int e g rit y Pro d uc t io n of im m uno re g ulat o ry m e t a b o lit e s Restoration of microbial SCFA ( Butyrate, Proprionate) Treatment of patients with hematol
Slide 15: ARES, a Pivotal Phase 3 Trial to Treat aGvHD in 3rd Line
MaaT Pharma MaaT013 aGvHD September 2024 15 ARES, a Pivotal Phase 3 Trial to Treat aGvHD in 3rd Line Showing “high efficacy and low toxicity” as Concluded by the DSMB Treatment Period D1, 5, 10 Primary follow-up Long-term follow-up Patients EOT Screening with SR-GI-aGvHD (D-14 to D-1) MaaT013 admini
Slide 16: The EAP Data Confirms Significant Improvement of Survival with High Level of Response
MaaT Pharma MaaT013 aGvHD October 2024 16 The EAP Data Confirms Significant Improvement of Survival with High Level of Response Global EAP Cohort - N=140 Patients’ profile GI-ORR Overall Survival Rate Patients (%) Survival (%) 100 60 8 40 26 50 20 39 0 0 0 90 180 270 360 450 540 Time Days High respo
Slide 17: In 3L, the EAP Data Confirms Frequent Responses to MaaT013 Leading to Prolonged Survival
MaaT Pharma MaaT013 aGvHD September 2024 17 In 3L, the EAP Data Confirms Frequent Responses to MaaT013 Leading to Prolonged Survival EAP: ARES like cohort – N=49, GI-aGvHD: 3L GI-ORR Overall Survival Rate Overall Survival Rate Patients (%) Survival (%) Survival (%) 6 mo 12 mo 18 mo 100 100 N=31 60 1
Slide 18: Remarkable Safety Profile of MaaT013 in Early Access Program
MaaT Pharma MaaT013 aGvHD October 2024 18 Remarkable Safety Profile of MaaT013 in Early Access Program Very good safety compared to historical data in heavily pre-treated and fragile population Protective immunorestoration, not immunosupression Bi-annual ANSM* safety report required on Expanded Acce
Slide 19: Proof-of-Concept with MaaT013 in Combination with ICI
MaaT Pharma POC - MaaT013 IO October 2024 19 Proof-of-Concept with MaaT013 in Combination with ICI In Metastatic Melanoma Serves as PoC for MaaT034 in combination with ICI MET-N
Slide 20: Checkpoint Inhibitors have revolutionized treatment but many patients show primary resistance
MaaT Pharma POC - MaaT013 IO October 2024 20 Checkpoint Inhibitors have revolutionized treatment of Solid Tumors but a large proportion of patients can’t benefit from it due to primary resistance Primary Resistance Rate to Immune Checkpoint 01 Around 19 million people diagnosed with cancer each year
Slide 21: Growing clinical evidence that a Full-Ecosystem Gut Microbiome influences efficacy of ICI
MaaT Pharma POC - MaaT013 IO October 2024 21 Growing clinical evidence that a Full-Ecosystem Gut Microbiome influences efficacy of ICI 2021 2023 2024 FMT from ICI-responders could FMT from healthy donors increases Microbiotherapy from healthy donors overcome resistance to ICI in response of aPD1 in
Slide 22: MaaT013 Evaluated in Phase 2 Randomized Clinical Trial in Melanoma
MaaT Pharma POC - MaaT013 IO October 2024 22 MaaT013 Evaluated in Phase 2 Randomized Clinical Trial in Melanoma Recruitment completed Ph. 2a PICASSO trial Key study endpoints after 23 weeks of treatment: Investigator led trial (Assistance Publique - Hôpitaux de Paris – sponsor) and in • MaaT013 safe
Slide 23: MaaT033 - The Oral Capsule for Adjunctive and Maintenance Therapy
MaaT Pharma MaaT033 October 2024 23 Ensuring Optimal Microbiota Function: MaaT033 - The Oral Capsule for Adjunctive and Maintenance Therapy Pooled microbiota : high-richness, high-diversity, full ecosystem, 01 Characteristics Microbiome Ecosystem Therapy containing Butycore® Non immunosuppressive tr
Slide 24: MaaT033: a Potential Adjunctive Treatment for Patients Receiving allo-HSCT
MaaT Pharma MaaT033 allo-HSCT October 2024 24 MaaT033: a Potential Adjunctive Treatment for Patients Receiving allo-HSCT → 387 patients in a randomized, double-blind, placebo-controlled → First positive DSMB (n=20*) in July 2024 – safety DSMB are planned every international study 6 months throughout
Slide 25: MaaT033 Aims to Slow Down Amyotrophic Lateral Sclerosis Progression
MaaT Pharma MaaT033 ALS October 2024 25 MaaT033 Aims to Slow Down Amyotrophic Lateral Sclerosis Progression Amyotrophic Lateral Sclerosis Study → Up to 15 patients in a pilot, open-label, Phase 1b study in France → Could affect up to 60,000 patients in US & EU by 2040 1 → Paralysis and death 3 to 5
Slide 26: Progressing the Next-Generation, Co-Cultured, Donor Independent MET-C Platform
Progressing the Next- Generation, Co-Cultured, Donor Independent MET-C Platform MET-C
Slide 27: MET-C Product Generation is Driven by Proprietary Predictive AI and Validation Processes
MaaT Pharma MET-C October 2024 27 MET-C Product Generation is Driven by MaaT Pharma’s Proprietary Predictive AI, Eubiotic Score and in vitro and in vivo validation processes In silico In vitro In vivo Clinic Candidate Products Upcoming Milestones Indication-specific HIT Products LEAD Products Donor-
Slide 28: End-to-End In-house cGMP Manufacturing
End-to-End In-house cGMP Manufacturing All MET
Slide 29: Europe's Largest Specialized cGMP Manufacturing Facility
MaaT Pharma All MET October 2024 29 Europe’s Largest 01 Specialized cGMP Fully integrated Manufacturing and development Manufacturing platform for a streamlined product development, Facility for Microbiome scaleup and GMP process. Ecosystem Therapies 02 A dedicated 1,600m2 site (expandable) to suppo
Slide 30: Key Takeaways
Key Takeaways
Slide 31: Multiple Near-Term Value Inflection Milestones
MaaT Pharma October 2024 31 Multiple Near-Term Value Inflection Milestones 2024/ Q1 2025 2025+ Finance MaaT013 (pooled enema) Revenues of MaaT013 in aGvHD MaaT013 (pooled enema) GvHD | Final Results (OS) of 1.7m€ for H1 2024 from Early GvHD | EAP long term follow-up EBMT24 IO Mela. | PICASSO P2a Res
Slide 32: A Robust Value Creation Strategy Driven by Leading Expertise in Microbiome-based Therapeutics
MaaT Pharma October 2024 32 A Robust Value Creation Strategy Driven by Leading Expertise in Microbiome-based Therapeutics MET-N MET-C MaaT03X MaaT034 MaaT033 MaaT013 Adressable Co-cultured caps. Co-cultured capsule Patients Pooled enema Pooled capsule Synthetic eubiotic microbiota Indication specifi
Slide 33: Corporate Social Responsibility
MaaT Pharma October 2024 33 Corporate Social Responsibility MaaT Pharma aims to become the source Patients are our priority. We are committed → Innovate and raise awareness to deliver of Microbiome excellence providing patients to our patients and to the protection of human better care, with safe an
Slide 34: Thank you
Thank you invest@maat-pharma.com